By Biogen Inc. | April 13, 2017

Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb

By Biogen Inc. | January 18, 2017

Biogen to Pay $1.25B in Licensing Agreement to Settle Patent Dispute